Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.

Carbohydrate and peptide-based antitumor vaccine constructs featuring clusters of both tumor associated carbohydrate antigens and mucin-like peptide epitopes have been designed, synthesized, and studied. The mucin-based epitopes are included to act, potentially, as T-cell epitopes in order to provoke a strong immune response. Hopefully the vaccine will simulate cell surface architecture, thereby provoking levels of immunity against cancer cell types displaying such characteristics. With this central idea in mind, we designed a new vaccine type against ovarian cancer. Following advances in glycohistology, our design is based on clusters of Gb(3) antigen and also incorporates a MUC5AC peptide epitope. The vaccine is among the most complex targeted constructs to be assembled by chemical synthesis to date. The strategy for the synthesis employed a Gb(3)-MUC5AC thioester cassette as a key building block. Syntheses of both nonconjugate and KLH-conjugated vaccines constructs have been accomplished.

[1]  E. Schmitt,et al.  Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. , 2008, Angewandte Chemie.

[2]  M. Wolfert,et al.  Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.

[3]  H. Kunz,et al.  Synthetic vaccines of tumor-associated glycopeptide antigens by immune-compatible thioether linkage to bovine serum albumin. , 2007, Angewandte Chemie.

[4]  S. Danishefsky,et al.  Promising agents at the interface of biology and oncology derived through chemical synthesis , 2007 .

[5]  I. Ishiwata,et al.  Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma‐derived cells with anticancer drug resistance , 2006, Cancer science.

[6]  P. Livingston,et al.  Cancer Vaccines Targeting Carbohydrate Antigens , 2006, Human vaccines.

[7]  O. Ouerfelli,et al.  Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. , 2006, Journal of the American Chemical Society.

[8]  A. Soran,et al.  Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma , 2006, BMC gastroenterology.

[9]  O. Ouerfelli,et al.  Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities , 2005, Expert review of vaccines.

[10]  G. Boons,et al.  Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. , 2005, Angewandte Chemie.

[11]  T. Lambert,et al.  Olefin Cross‐Metathesis: A Powerful Tool for Constructing Vaccines Composed of Multimeric Antigens , 2005 .

[12]  T. O'brien,et al.  Definition of an Immunogenic Region Within the Ovarian Tumor Antigen Stratum Corneum Chymotryptic Enzyme , 2005, Clinical Cancer Research.

[13]  M. Kris,et al.  Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin , 2004, Clinical Cancer Research.

[14]  H. Kunz,et al.  Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4. , 2004, Chemistry.

[15]  S. Danishefsky,et al.  Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Harris,et al.  NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells 1 , 2003, The Journal of Immunology.

[17]  Chi‐Huey Wong.  Carbohydrate-based drug discovery. , 2003 .

[18]  I. L. Le Poole,et al.  Emerging strategies in tumor vaccines. , 2002, Current opinion in oncology.

[19]  T. O'brien,et al.  Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer , 2002, Expert review of anticancer therapy.

[20]  B. Yin,et al.  Molecular Cloning of the CA125 Ovarian Cancer Antigen , 2001, The Journal of Biological Chemistry.

[21]  Larry Norton,et al.  Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Danishefsky,et al.  Pursuit of optimal carbohydrate-based anticancer vaccines: preparation of a multiantigenic unimolecular glycopeptide containing the Tn, MBr1, and Lewis(y) antigens. , 2001, Journal of the American Chemical Society.

[23]  S. Hintermann,et al.  Design and Synthesis of Ley-Bearing Glycopeptides that Mimic Cell Surface Ley Mucin Glycoprotein Architecture , 2000 .

[24]  M. Peyton,et al.  Immunization of ovarian cancer patients with a synthetic Lewisy‐protein conjugate vaccine: A phase 1 trial , 2000, International journal of cancer.

[25]  A. Zatorski,et al.  A second generation synthesis of the MBr1 (globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages. , 2000, Chemistry.

[26]  Allen,et al.  From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix. , 2000, Angewandte Chemie.

[27]  S. Barratt-Boyes,et al.  Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Schmidt,et al.  New aspects of glycoside bond formation , 1999 .

[29]  H. Scher,et al.  Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. P. Harrity,et al.  A Recyclable Ru-Based Metathesis Catalyst , 1999 .

[31]  R. Dodge,et al.  Mucin gene expression in ovarian cancers. , 1998, Cancer research.

[32]  S. Kuduk,et al.  Synthetic and Immunological Studies on Clustered Modes of Mucin-Related Tn and TF O-Linked Antigens: The Preparation of a Glycopeptide-Based Vaccine for Clinical Trials against Prostate Cancer† , 1998 .

[33]  P. Ciborowski,et al.  Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. , 1998, Cancer research.

[34]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Kawakami,et al.  Synthesis of reaper, a cysteine-containing polypeptide, using a peptide thioester in the presence of silver chloride as an activator , 1998 .

[36]  J. Kihlberg,et al.  Solid‐Phase Synthesis of Glycopeptides: Immunological Studies with T Cell Stimulating Glycopeptides , 1997 .

[37]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group‐related antigens , 1997, International journal of cancer.

[38]  C. Cordon-Cardo,et al.  Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides , 1997, International journal of cancer.

[39]  S. Danishefsky,et al.  Immunization of Mice with a Fully Synthetic Globo H Antigen Results in Antibodies against Human Cancer Cells: A Combined Chemical—Immunological Approach to the Fashioning of an Anticancer Vaccine , 1997 .

[40]  J. Davies,et al.  Glycoconjugates facing the outside world. , 1997, Biochemical Society transactions.

[41]  K. Lloyd,et al.  Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. , 1996, Cancer research.

[42]  B. Yin,et al.  Serological and immunochemical analysis of Lewis Y (Ley) blood group antigen expression in epithelial ovarian cancer , 1996, International journal of cancer.

[43]  P. Livingston.  Augmenting the immunogenicity of carbohydrate tumor antigens. , 1995, Seminars in cancer biology.

[44]  K. Lloyd,et al.  High performance anion exchange chromatography of reduced oligosaccharides from sialomucins , 1991, Glycoconjugate Journal.

[45]  K. Nicolaou,et al.  A practical and enantioselective synthesis of glycosphingolipids and related compounds. Total synthesis of globotriaosylceramide (Gb3) , 1988 .

[46]  R. Townsend,et al.  Separation of positional isomers of oligosaccharides and glycopeptides by high-performance anion-exchange chromatography with pulsed amperometric detection. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Danishefsky,et al.  Synthetic Glycopeptide-Based Vaccines , 2006 .

[48]  C. Lingwood,et al.  Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. , 1998, Acta biochimica Polonica.

[49]  R. Dwek,et al.  Concepts and principles of O-linked glycosylation. , 1998, Critical reviews in biochemistry and molecular biology.

[50]  B. Rosen,et al.  Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. , 1997, Oncology research.